Tag: substances

SUGAR LAND, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (NYSE: CVI, “CVR Energy” or the “Company”) today announced second quarter 2025 net loss attributable to CVR Energy stockholders of $114 million, or $1.14 per diluted share, compared to second quarter 2024 net income attributable to CVR Energy stockholders of $21 million, or 21 cents per diluted share. Adjusted loss for the second quarter of 2025 was 23 cents per diluted share, compared to adjusted earnings per diluted share of 9 cents in the second quarter of 2024. Net loss for the second quarter of 2025 was $90 million, compared to net income of $38 million in the second quarter of 2024. Second quarter 2025 EBITDA loss was $24 million, compared to second quarter 2024 EBITDA of $103 million. Adjusted EBITDA for the second quarter of 2025 was $99 million, compared to adjusted EBITDA of $87 million in the second quarter of 2024.

New York City, NY, July 29, 2025 (GLOBE NEWSWIRE) --

In 2025, PhenQ is setting a new standard for belly fat burners with its research-driven, natural solution, providing powerful, long-lasting support for a slimmer, healthier stomach without injections or unwanted side effects, and supporting a healthier, more sustainable lifestyle.

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.